<DOC>
	<DOCNO>NCT00682721</DOCNO>
	<brief_summary>We examine effect suppressive valacyclovir therapy stability vaginal flora woman seropositive HSV-2 . We preliminary data suggest presence HSV-2 increase risk Group B Streptococcus colonization well many deleterious organism ( e.g . Streptococcus pseudoporcinus ) , addition increase risk acquisition BV-associated vaginal flora . We examine effect suppressive therapy vaginal flora HSV-2 seropositive woman .</brief_summary>
	<brief_title>Valacyclovir Suppression Improve Stability Vaginal Flora Among HSV-2 Seropositive Women</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Screening Women 1840 year age time screen Willing screen HSV2 use rapid , FDA approve test Using effective method birth control ( example effective method birth control : woman practice abstinence x 90 day , hormonal birth control , consistent condom use , bilateral tubal ligation , partner vasectomy ) Screening Pregnant nursing mother Use antimicrobial agent ( vaginal systemic ) treatment condition within 7 day Presence intrauterine device Allergy hypersensitivity valcyclovir nucleoside analogue Enrollment Women 1840 Years age time screen HSV2 seropositive determine rapid HSV2 test Using effective method birth control ( example effective method birth control : woman practice abstinence x 90 day , hormonal birth control , consistent condom use , bilateral tubal ligation , partner vasectomy ) Willing avoid use intravaginal product study period Capable provide write informed consent Capable cooperate extent degree require protocol Enrollment Pregnancy ( woman urine pregnancy test prior randomization treatment ) nursing mother Menopausal woman Use antimicrobial agent ( vaginal systemic ) treatment condition within 7 day study enrollment Known immunocompromised state Significant Medical disorder precludes accurate evaluation participant condition Presence intrauterine device History significant hepatic renal impairment Sensitivity/allergy valacyclovir nucleoside analogues history acyclovir valacyclovir resistant HSV infection Participation study use investigational product past 30 day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Bacterial Vaginosis</keyword>
	<keyword>Herpes Simplex Virus Type II</keyword>
</DOC>